Glucagon-like peptide 1 precursor

The **glucagon-like peptide 1 precursor** is commonly known as **proglucagon**, a preprohormone encoded by the GCG gene. It is processed in a tissue-specific manner to yield several biologically active peptides, including glucagon (pancreas) and glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) (intestine)[2][1]. In the gut, proglucagon is specifically cleaved to generate GLP-1 and GLP-2, which are key regulators of glucose metabolism and homeostasis. The physiological actions of GLP-1 include potentiation of insulin secretion in response to glucose, and this is the basis for the development of GLP-1 receptor agonist drugs for type 2 diabetes and obesity[3][6]. **However, "glucagon-like peptide 1 precursor" is not itself a therapeutic target**; rather, its processed products are, especially GLP-1 and the GLP-1 receptor[3][5]. GLP-1 receptor, not the precursor, is directly targeted by drugs such as exenatide, liraglutide, semaglutide, and dulaglutide, used in diabetes and obesity therapies[3]. **Summary note:** "Glucagon-like peptide 1 precursor" is not a molecule directly targeted by drugs or considered a therapeutic target; the actual target of clinical importance is the "glucagon-like peptide 1 receptor" (GLP-1R). The precursor is therefore incorrectly listed as a standalone target for most "target" purposes[3].

Other names

ProglucagonGCG gene product